Union Pacific (NYSE:UNP) reported quarterly earnings of $3.19 per share which beat the analyst consensus estimate of $3.08 by 3.57 percent. This is a 24.12 percent increase over earnings of $2.57 per share from the same period last year. The company reported quarterly sales of $6.60 billion which beat the analyst consensus estimate of $6.42 billion by 2.80 percent. This is a 18.58 percent increase over sales of $5.57 billion the same period last year.
CymaBay Therapeutics Announced Collaboration with Kaken Pharmaceutical to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis; Kaken to Make Upfront Payment To Cymabay Of ~$34M Plus Milestone Payments Up To ~$128.4M And Royal…
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced today that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") for the development and commercialization in Japan of CymaBay's investigational drug seladelpar for the treatment of primary biliary cholangitis ("PBC").
